Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Transitional Cell Carcinoma: early-phase trial registry
A small indexed set (5 trials) with no open enrollment listed right now.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count
Transitional Cell Carcinoma: 5 US clinical trials tracked, none currently recruiting.
Transitional Cell Carcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 2 of these trials.
Enrollment posture brief
Registry condition transitional-cell-carcinoma
OPEN 0 | RECR 0% | LATE 0 | EARLY 4 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Transitional Cell Carcinoma has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Transitional Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Transitional Cell Carcinoma is recruiting below its size-band peers.
0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Transitional Cell Carcinoma research.
Bristol-Myers Squibb accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Transitional Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 34 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Transitional Cell Carcinoma research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT02420847
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
Bristol-Myers Squibb
NCT00633789
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Bristol-Myers Squibb
NCT00389155
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Wake Forest University Health Sciences
NCT02581982
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
Memorial Sloan Kettering Cancer Center
NCT00612326
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Transitional Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Transitional Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Transitional Cell Carcinoma page
5 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Transitional Cell Carcinoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Bristol-Myers Squibb sponsors the most Transitional Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Transitional Cell Carcinoma condition card totals 5 registered trials; most-linked intervention MRI and PET scanning procedures; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.